Literature DB >> 26506932

Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge.

M T McClain1,2,3, R Henao1,4, J Williams2, B Nicholson2, T Veldman1, L Hudson1, E L Tsalik1,2,3, R Lambkin-Williams5, A Gilbert5, A Mann5, G S Ginsburg1, C W Woods1,2,3.   

Abstract

Exposure to influenza virus triggers a complex cascade of events in the human host. In order to understand more clearly the evolution of this intricate response over time, human volunteers were inoculated with influenza A/Wisconsin/67/2005 (H3N2), and then had serial peripheral blood samples drawn and tested for the presence of 25 major human cytokines. Nine of 17 (53%) inoculated subjects developed symptomatic influenza infection. Individuals who will go on to become symptomatic demonstrate increased circulating levels of interleukin (IL)-6, IL-8, IL-15, monocyte chemotactic protein (MCP)-1 and interferon (IFN) gamma-induced protein (IP)-10 as early as 12-29 h post-inoculation (during the presymptomatic phase), whereas challenged patients who remain asymptomatic do not. Overall, the immunological pathways of leucocyte recruitment, Toll-like receptor (TLR)-signalling, innate anti-viral immunity and fever production are all over-represented in symptomatic individuals very early in disease, but are also dynamic and evolve continuously over time. Comparison with simultaneous peripheral blood genomics demonstrates that some inflammatory mediators (MCP-1, IP-10, IL-15) are being expressed actively in circulating cells, while others (IL-6, IL-8, IFN-α and IFN-γ) are probable effectors produced locally at the site of infection. Interestingly, asymptomatic exposed subjects are not quiescent either immunologically or genomically, but instead exhibit early and persistent down-regulation of important inflammatory mediators in the periphery. The host inflammatory response to influenza infection is variable but robust, and evolves over time. These results offer critical insight into pathways driving influenza-related symptomatology and offer the potential to contribute to early detection and differentiation of infected hosts.
© 2015 British Society for Immunology.

Entities:  

Keywords:  cytokines; humans; influenza; viral infection

Mesh:

Substances:

Year:  2015        PMID: 26506932      PMCID: PMC4750592          DOI: 10.1111/cei.12736

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity.

Authors:  G G JACKSON; H F DOWLING; I G SPIESMAN; A V BOAND
Journal:  AMA Arch Intern Med       Date:  1958-02

2.  Induction of TNF-alpha in human macrophages by avian and human influenza viruses.

Authors:  Yuwarat Monteerarat; Saori Sakabe; Somying Ngamurulert; Sirawat Srichatraphimuk; Wasana Jiamtom; Kridsada Chaichuen; Arunee Thitithanyanont; Parichart Permpikul; Taweesak Songserm; Pilaipan Puthavathana; Chairul A Nidom; Le Quynh Mai; Kiyoko Iwatsuki-Horimoto; Yoshihiro Kawaoka; Prasert Auewarakul
Journal:  Arch Virol       Date:  2010-06-09       Impact factor: 2.574

3.  Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Authors:  Matthew J Memoli; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Kathleen Proudfoot; Sarah Fargis; Matthew Stein; Rebecca L Dunfee; Pamela A Shaw; Richard T Davey; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

4.  Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia.

Authors:  Nelson Lee; Paul K S Chan; Chun Kwok Wong; Ka-Tak Wong; Kin-Wing Choi; Gavin M Joynt; Philip Lam; Martin C W Chan; Bonnie C K Wong; Grace C Y Lui; Winnie W Y Sin; Rity Y K Wong; Wai-Yip Lam; Apple C M Yeung; Ting-Fan Leung; Hing-Yu So; Alex W Y Yu; Joseph J Y Sung; David S C Hui
Journal:  Antivir Ther       Date:  2011

5.  Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans.

Authors:  Aimee K Zaas; Minhua Chen; Jay Varkey; Timothy Veldman; Alfred O Hero; Joseph Lucas; Yongsheng Huang; Ronald Turner; Anthony Gilbert; Robert Lambkin-Williams; N Christine Øien; Bradly Nicholson; Stephen Kingsmore; Lawrence Carin; Christopher W Woods; Geoffrey S Ginsburg
Journal:  Cell Host Microbe       Date:  2009-08-06       Impact factor: 21.023

6.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Authors:  F G Hayden; J J Treanor; R S Fritz; M Lobo; R F Betts; M Miller; N Kinnersley; R G Mills; P Ward; S E Straus
Journal:  JAMA       Date:  1999-10-06       Impact factor: 56.272

7.  Gene expression profiles during in vivo human rhinovirus infection: insights into the host response.

Authors:  David Proud; Ronald B Turner; Birgit Winther; Shahina Wiehler; Jay P Tiesman; Tim D Reichling; Kenton D Juhlin; Andy W Fulmer; Begonia Y Ho; Amy A Walanski; Cathy L Poore; Haruko Mizoguchi; Lynn Jump; Marsha L Moore; Claudine K Zukowski; Jeffrey W Clymer
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

8.  Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells.

Authors:  M C W Chan; C Y Cheung; W H Chui; S W Tsao; J M Nicholls; Y O Chan; R W Y Chan; H T Long; L L M Poon; Y Guan; J S M Peiris
Journal:  Respir Res       Date:  2005-11-11

9.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.

Authors:  Menno D de Jong; Cameron P Simmons; Tran Tan Thanh; Vo Minh Hien; Gavin J D Smith; Tran Nguyen Bich Chau; Dang Minh Hoang; Nguyen Van Vinh Chau; Truong Huu Khanh; Vo Cong Dong; Phan Tu Qui; Bach Van Cam; Do Quang Ha; Yi Guan; J S Malik Peiris; Nguyen Tran Chinh; Tran Tinh Hien; Jeremy Farrar
Journal:  Nat Med       Date:  2006-09-10       Impact factor: 53.440

10.  Re-emergence of fatal human influenza A subtype H5N1 disease.

Authors:  J S M Peiris; W C Yu; C W Leung; C Y Cheung; W F Ng; J M Nicholls; T K Ng; K H Chan; S T Lai; W L Lim; K Y Yuen; Y Guan
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

View more
  14 in total

1.  GPER1 is required to protect fetal health from maternal inflammation.

Authors:  Alfred T Harding; Marisa A Goff; Heather M Froggatt; Jean K Lim; Nicholas S Heaton
Journal:  Science       Date:  2021-01-15       Impact factor: 47.728

Review 2.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

3.  Corticosteroids as adjunctive therapy in the treatment of influenza.

Authors:  Louise Lansbury; Chamira Rodrigo; Jo Leonardi-Bee; Jonathan Nguyen-Van-Tam; Wei Shen Lim
Journal:  Cochrane Database Syst Rev       Date:  2019-02-24

Review 4.  Nonrespiratory sites of influenza-associated disease: mechanisms and experimental systems for continued study.

Authors:  Heather M Froggatt; Nicholas S Heaton
Journal:  FEBS J       Date:  2022-02-07       Impact factor: 5.622

Review 5.  Evolution and Virulence of Influenza A Virus Protein PB1-F2.

Authors:  Ram P Kamal; Irina V Alymova; Ian A York
Journal:  Int J Mol Sci       Date:  2017-12-29       Impact factor: 5.923

6.  Epidemiological and Serological Investigation into the Role of Gestational Maternal Influenza Virus Infection and Autism Spectrum Disorders.

Authors:  Milada Mahic; Xiaoyu Che; Ezra Susser; Bruce Levin; Ted Reichborn-Kjennerud; Per Magnus; Camilla Stoltenberg; Lokendrasingh Chauhan; Thomas Briese; Michaeline Bresnahan; Pål Surén; Mady Hornig; Siri Mjaaland; W Ian Lipkin
Journal:  mSphere       Date:  2017-06-21       Impact factor: 4.389

Review 7.  The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.

Authors:  Rob Lambkin-Williams; Nicolas Noulin; Alex Mann; Andrew Catchpole; Anthony S Gilbert
Journal:  Respir Res       Date:  2018-06-22

8.  Adaptation of influenza A (H7N9) virus in primary human airway epithelial cells.

Authors:  Daniel Tsung-Ning Huang; Chun-Yi Lu; Ya-Hui Chi; Wan-Ling Li; Luan-Yin Chang; Mei-Ju Lai; Jin-Shing Chen; Wen-Ming Hsu; Li-Min Huang
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

Review 9.  Influenza, evolution, and the next pandemic.

Authors:  David S Fedson
Journal:  Evol Med Public Health       Date:  2018-10-03

10.  A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection.

Authors:  Slim Fourati; Aarthi Talla; Mehrad Mahmoudian; Joshua G Burkhart; Riku Klén; Ricardo Henao; Thomas Yu; Zafer Aydın; Ka Yee Yeung; Mehmet Eren Ahsen; Reem Almugbel; Samad Jahandideh; Xiao Liang; Torbjörn E M Nordling; Motoki Shiga; Ana Stanescu; Robert Vogel; Gaurav Pandey; Christopher Chiu; Micah T McClain; Christopher W Woods; Geoffrey S Ginsburg; Laura L Elo; Ephraim L Tsalik; Lara M Mangravite; Solveig K Sieberts
Journal:  Nat Commun       Date:  2018-10-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.